INTICA Biomedical
Lexington
About INTICA Biomedical
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
Company Facts
- Operating status: Closed
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $640.0K
- Last round: Debt Financing (Mar 2012)
- Website: inticabio.com
- Phone: 7812400074
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/intica-biomedical-1692212 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.